Brian D. Dayton

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

Terry J. Opgenorth, Andrew Adler, Samuel V. Calzadilla et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 210 citations

Medicine, Pharmacology, Physiology +15

Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · 2013 · 182 citations

Medicine, Oncology, Pharmacology +8

Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease.

Thomas D. Meek, Brian D. Dayton, Brian W. Metcalf et al. · Proceedings of the National Academy of Sciences · 1989 · 177 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Peptide substrates and inhibitors of the HIV-1 protease

Michael L. Moore, William M. Bryan, Stephen A. Fakhoury et al. · Biochemical and Biophysical Research Communications · 1989 · 161 citations

Life Sciences, Biochemistry, Molecular Biology +14